Zuletzt geändert von Thomas Brinkmeier am 2025/04/25 20:40
<
Von Version < 2.1 >
bearbeitet von Thomas Brinkmeier
am 2019/02/02 21:13
Auf Version < 20.1 >
bearbeitet von Thomas Brinkmeier
am 2024/09/07 22:03
>
Änderungskommentar: Es gibt keinen Kommentar für diese Version

Zusammenfassung

Details

Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf
Author
... ... @@ -1,0 +1,1 @@
1 +XWiki.Dermatologie_Kompendium
Größe
... ... @@ -1,0 +1,1 @@
1 +620.9 KB
Inhalt
Wikiderm.EntryClass[0]
Eintrag
... ... @@ -59,15 +59,63 @@
59 59  (% class="Bullet" %)-(%%) Pyoderma gangraenosum
60 60  
61 61  (% class="Eintrag-2" %)
62 -(% class="Feature" %)TF:(%%) Infekte
62 +(% class="Feature" %)TF:(%%) (% class="Bullet" %)-(%%) Infekte
63 63  
64 64  (% class="Ebene-2" %)
65 65  (% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV
66 66  
67 +(% class="Ebene-1" %)
68 +(% class="Bullet" %)-(%%) Dupilumab
69 +
70 +(% class="Ebene-2" %)
71 +(% class="Feature" %)Lit:(%%) Australas J Dermatol. 2023 Nov 27. [[http:~~/~~/doi.org/10.1111/ajd.14190>>url:http://doi.org/10.1111/ajd.14190]]
72 +
67 67  (% class="Eintrag-2" %)
68 -(% class="Feature" %)DD:(%%) (% class="Abbreviation" %)AGEP(%%), Dermatitis herpetiformis, eosinophile pustulöse Follikulitis Ofuji, Impetigo contagiosa, Pemphigus foliaceus, Psoriasis pustulosa
74 +(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) AGEP
69 69  
76 +(% class="Ebene-1" %)
77 +(% class="Bullet" %)-(%%) Dermatitis herpetiformis
78 +
79 +(% class="Ebene-1" %)
80 +(% class="Bullet" %)-(%%) eosinophile pustulöse Follikulitis Ofuji
81 +
82 +(% class="Ebene-1" %)
83 +(% class="Bullet" %)-(%%) Impetigo contagiosa
84 +
85 +(% class="Ebene-1" %)
86 +(% class="Bullet" %)-(%%) Pemphigus foliaceus
87 +
88 +(% class="Ebene-1" %)
89 +(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
90 +
91 +(% class="Ebene-2" %)
92 +(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
93 +
94 +(% class="Ebene-2" %)
95 +(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
96 +
97 +(% class="Ebene-1" %)
98 +(% class="Bullet" %)-(%%) Tinea incognito
99 +
100 +(% class="Ebene-2" %)
101 +(% class="Feature" %)Lit:(%%) [[Kalkan, G., Demirseren, D. D, Güney, C. A, & Aktaş, A. (2020). A case of tinea incognito mimicking subcorneal pustular dermatosis. Dermatology Online Journal, 26(2)>>url:https://escholarship.org/uc/item/46g9x55w]]
102 +
70 70  (% class="Eintrag-2" %)
104 +(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}}
105 +
106 +(% class="Ebene-1" %)
107 +(% class="Bullet" %)-(%%) Open Access Maced J Med Sci. 2020 Jun 05; 8(T1):12-15. [[https:~~/~~/doi.org/10.3889/oamjms.2020.4870>>url:https://doi.org/10.3889/oamjms.2020.4870]]
108 +
109 +(% class="Ebene-1" %)
110 +(% class="Bullet" %)-(%%) International Journal of Women's Dermatology, Volume 6, Issue 3, 2020, Pages 131-136, ISSN 2352-6475, [[https:~~/~~/doi.org/10.1016/j.ijwd.2020.02.003>>url:https://doi.org/10.1016/j.ijwd.2020.02.003]]
111 +
112 +(% class="Ebene-1" %)
113 +(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]]
114 +
115 +(% class="Ebene-1" %)
116 +(% class="Bullet" %)-(%%) JAAD Case Rep. 2022 Jan 21;21:185-188. [[http:~~/~~/doi.org/10.1016/j.jdcr.2021.04.039>>url:http://doi.org/10.1016/j.jdcr.2021.04.039]]
117 +
118 +(% class="Eintrag-2" %)
71 71  (% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal
72 72  
73 73  (% class="Ebene-2" %)
... ... @@ -74,6 +74,12 @@
74 74  (% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**)
75 75  
76 76  (% class="Ebene-2" %)
125 +(% class="Bullet" %)-(%%) Mometasonfuroat
126 +
127 +(% class="Ebene-3" %)
128 +(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]]
129 +
130 +(% class="Ebene-2" %)
77 77  (% class="Bullet" %)-(%%) Tacalcitol
78 78  
79 79  (% class="Ebene-3" %)
... ... @@ -80,7 +80,7 @@
80 80  (% class="Feature" %)Lit:(%%) J Dermatol 2000; 27: 669-72
81 81  
82 82  (% class="Ebene-3" %)
83 -(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
137 +(% class="Feature" %)PT:(%%) CR
84 84  
85 85  (% class="Ebene-3" %)
86 86  (% class="Feature" %)Altn:(%%) Maxacalcitol
... ... @@ -89,8 +89,14 @@
89 89  (% class="Feature" %)Lit:(%%) Clin Exp Dermatol. 2015 May 19. [[http:~~/~~/doi.org/10.1111/ced.12680>>url:http://doi.org/10.1111/ced.12680]]
90 90  
91 91  (% class="Ebene-5" %)
92 -(% class="Feature" %)Lit:(%%) (% class="Abbreviation" %)CR(%%)
146 +(% class="Feature" %)Lit:(%%) CR
93 93  
148 +(% class="Ebene-2" %)
149 +(% class="Bullet" %)-(%%) Dapson Gel
150 +
151 +(% class="Ebene-3" %)
152 +(% class="Feature" %)Lit:(%%) J Dermatol. 2019 Jun 24. [[http:~~/~~/doi.org/10.1111/1346-8138.14953>>url:http://doi.org/10.1111/1346-8138.14953]]
153 +
94 94  (% class="Ebene-1" %)
95 95  (% class="Bullet" %)-(%%) systemisch
96 96  
... ... @@ -98,7 +98,7 @@
98 98  (% class="Bullet" %)-(%%) Dapson
99 99  
100 100  (% class="Ebene-3" %)
101 -(% class="Feature" %)Bed:(%%) (% class="Abbreviation" %)GS(%%)
161 +(% class="Feature" %)Bed:(%%) GS
102 102  
103 103  (% class="Ebene-3" %)
104 104  (% class="Feature" %)Dos:(%%) 100-150 mg/Tag
... ... @@ -134,6 +134,15 @@
134 134  (% class="Feature" %)Lit:(%%) Dermatol Ther. 2019 Jan 14:e12818. [[http:~~/~~/doi.org/10.1111/dth.12818>>url:http://doi.org/10.1111/dth.12818]]
135 135  
136 136  (% class="Ebene-2" %)
197 +(% class="Bullet" %)-(%%) Apremilast
198 +
199 +(% class="Ebene-3" %)
200 +(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) Australas J Dermatol. 2020 Feb 11. [[http:~~/~~/doi.org/10.1111/ajd.13253>>url:http://doi.org/10.1111/ajd.13253]]
201 +
202 +(% class="Ebene-3" %)
203 +(% class="Bullet" %)-(%%) Australas J Dermatol. 2023 Aug;64(3):e310-e312. [[http:~~/~~/doi.org/10.1111/ajd.14073>>url:http://doi.org/10.1111/ajd.14073]]
204 +
205 +(% class="Ebene-2" %)
137 137  (% class="Bullet" %)-(%%) Anti-TNF-alpha
138 138  
139 139  (% class="Ebene-3" %)
... ... @@ -140,14 +140,8 @@
140 140  (% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
141 141  
142 142  (% class="Ebene-4" %)
143 -(% class="Feature" %)Phar:(%%) Remicade^^®^^
212 +(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
144 144  
145 -(% class="Ebene-4" %)
146 -(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
147 -
148 -(% class="Ebene-4" %)
149 -(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
150 -
151 151  (% class="Ebene-3" %)
152 152  (% class="Bullet" %)-(%%) Adalimumab
153 153  
... ... @@ -156,3 +156,10 @@
156 156  
157 157  (% class="Ebene-5" %)
158 158  (% class="Feature" %)PT:(%%) CR
222 +
223 +(% class="Ebene-2" %)
224 +(% class="Bullet" %)-(%%) Guselkumab
225 +
226 +(% class="Ebene-3" %)
227 +(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]]
228 +

Artikelinhalt

©WIKIDERM GmbH • Kontakt • FAQ • Impressum • Nutzungsbedingungen • Datenschutzerklärung • Facebook